ABSTRACT

BACKGROUND: Mucosal affection may be a direct cytotoxic or cytostatic effect of methotrexate.

OBJECTIVE: To highlight the diagnostic procedure and treatment intervention erythema multiforme complicating methotrexate-induced allergic stomatitis.

CASE REPORT: The patient was a 60-year-old man suffering from stomatitis that rapidly developed into erythema multiforme. The patient had been prescribed methotrexate to treat rheumatoid arthritis. The patient presented with painful ulceration of the vermilion border of the upper and lower lips covered with necrotic tissues. We made a tentative diagnosis of methotrexate induced allergic stomatitis. On the patient’s second visit to the clinic, the lesion had developed into crusted and haemorrhagic ulceration with erythematous patches on the lips. The patient was now complaining of weakness, fever and occasional seizure attack. Examination of the upper and lower extremities revealed bilateral bullous eruptions. The definitive diagnosis was that of erythema multiforme complicating methotrexate induced allergic stomatitis. Withdrawal of the methotrexate yielded positive result with complete resolution of the lesions after 12 days of drug withdrawal.

CONCLUSION: Early diagnosis of adverse drug reactions is essential for effective treatment, to avoid untoward systemic complications. WAJM 2011; 30(5): 377–379.

Keywords: Methotrexate, Allergic Stomatitis, Erythema multiforme, complications.

RÉSUMÉ

CONTEXTE: l’affectation des muqueuses peut être un effet cytotoxique direct ou cytostatique de méthotrexate.

OBJECTIF: Pour mettre en évidence la procédure de diagnostic et d’érithème polymorphe de traitement d’intervention complique induite par le méthotrexate stomatite allergique.


Mots-clés: méthotrexate, stomatite allergique, érythème polymorphe, de complications.
INTRODUCTION

Allergic stomatitis is a known side effect of methotrexate administered either orally or parenterally. The mucosal alteration in this lesion may result from direct cytotoxic or cytostatic effect of the drug on the dividing epithelial cells, myelosuppression or alteration of microbial flora. The condition presents clinically as painful, erythematous, erosive or ulcerative lesion, with the nonkeratinized mucosa often affected. Pseudomembranous necrotic surface, with widespread sloughing and ulceration may arise within days of commencement of cytotoxic drug therapy. Treatment of the lesion is by identification and withdrawal of the offending drug. Systemic corticosteroid therapy in cases with mucosal reactive lesion gives excellent prognosis.

The name ‘erythema multiforme’ originated from Von Hebra. The development of erythema multiforme (EM) is a rare adverse reaction to methotrexate. EM presents as acute mucocutaneous inflammatory and hypersensitivity reaction characterised by a skin eruption; with symmetric erythematous, oedematous or bullous lesions of the skin or mucous membranes. Although, the lesion has “multiple forms”, it is divided into two overlapping subgroups – the minor and major types. EM minor represents a localized eruption of the skin with mild or no mucosal involvement, corresponding to the initial description of Von Hebra. EM major or Stevens-Johnson syndrome (SJS) is more severe; classically involving two or more mucous membranes, with more variable skin involvement. This latter form is a potentially life-threatening disorder.

Although the pathogenesis of the disease is unknown, there are many implicated precipitating factors, particularly herpes simplex infection. EM may occur due to drug therapy such as sulphonamides, barbiturates, antibiotics, phenolphthalein-containing laxatives, anti-convulsants, non-steroidal anti-inflammatory drugs, chloromezane and allopurinol. However, patients with EM rarely give a positive drug history. Another possible trigger for the development of EM is radiation therapy. EM can be an immune mediated reaction possibly related to circulating immune complexes. Nevertheless, many cases of EM appear to arise spontaneously.

We report a case of erythema multiforme complicating an initially diagnosed methotrexate induced allergic stomatitis, in a 60-year-old patient that was receiving treatment for rheumatoid arthritis, to highlight the diagnostic procedure and treatment intervention of this rare case.

CASE REPORT

A 60-year-old male patient presented at the Oral and Maxillofacial Surgery and Pathology Clinic of the University of Benin Teaching Hospital, Benin City, Nigeria with a painful ulceration of the vermilion border of the upper and lower lips and oral mucosa [Figure 1]. The lesion had a surface covered by pseudomembranous necrotic tissue. A detailed history revealed that the patient was suffering from rheumatoid arthritis and placed on a daily dose of 5mg of methotrexate for over two weeks by an orthopaedic surgeon.

An initial diagnosis of methotrexate-induced allergic stomatitis was made and the patient placed on warm saline mouth rinse eight times daily for two weeks, soft diet and 12.5mg promethazine eight hourly for a week. In addition, amoxycillin 500mg and methronidazole 400mg were administered 8 hourly daily for five days. We informed the orthopaedic surgeon that the patient was probably reacting adversely to methotrexate and advised a change of medication. We also took oral swab for microscopy, culture and sensitivity.

On the patient’s second visit to the clinic, the lesion had developed into crusted and hemorrhagic ulceration with erythematous patches on the lips. The patient was now complaining of weakness, fever and occasional seizure attacks. Examination of the upper and lower extremities revealed bilateral bullous eruptions [Figure 2]. The definitive diagnosis was that of erythema multiforme complicating methotrexate induced allergic stomatitis. The oral swab culture revealed that there was a secondary infection by *Staphylococcus aureus* sensitive to the drug ciprofloxacin. We placed the patient on ciprofloxacin 500mg 12 hourly for five days. In addition to this treatment, an advice to the orthopaedic surgeon to withdraw the drug yielded positive result with complete resolution of the skin and oral mucosal lesions after 12 days of drug withdrawal [Figure 3].

DISCUSSION

The hallmark of EM is a target lesion with variable mucous membrane involvement; mucosal involvement is usually limited to the oral mucosal. Similarly, this report showed an initial oral mucosal involvement, followed by cutaneous lesions affecting both the upper and lower extremities. The lesion presented as methotrexate induced...
allergic stomatitis and rapidly developed into EM within a few days. Although, literature reports vary from 0% to 18% association of EM with medications.1,10 This is the first reported case of EM arising as a complication of methotrexate therapy in our centre. Erythema multiforme is a known adverse reaction to methotrexate.14 The adverse cutaneous drug eruptions may vary from benign maculopapular rash to Lyell syndrome, which depends mainly on the host response to the drug. Although the precise pathogenesis is still unknown, EM appears to be the consequence of a cytotoxic immunological reaction against the keratinocytes expressing non-self antigens.15

Our report showed that the lesion occurred in a 60-year-old male patient, in contrast to previous reports that clearly identified the lesion frequently in younger individuals.2,3,5,10 Although EM frequently occurs in males, the incidence of drug-related EM is similar in males and females.7 Soteres et al16 reported a similar case of methotrexate induced EM with lip swelling and generalised rash following oral administration of methotrexate. The rashes resolved after withdrawal of methotrexate therapy and several days of administering diphenhydramine. However, the classical presentation of this case was severe compared to those reported by Soteres et al.16 Similarly, there was complete resolution of the skin and mucosal lesions within 2 weeks of initial presentation, following antihistamine therapy and withdrawal of the causative drug. We support a change to alternative medication following withdrawal of methotrexate, especially for treatment of neoplastic lesions, as recommended by Taylor et al.14

The oral microbiological diagnosis of the infective organism suggests that there was secondary infection, whereas the known primary infective organisms in EM are herpes simplex virus and mycoplasma pneumonia.2,3,13,17

In conclusion, this report highlights the diagnostic procedures and treatment intervention to control methotrexate-induced erythema multiforme, a rare adverse drug reaction. Early diagnosis of adverse drug reactions is essential for effective treatment, to avoid untoward systemic complications.

ACKNOWLEDGEMENT
We wish to acknowledge the American Association for Dental Research and International Association for Dental Research, for granting us the opportunity to carry out a poster presentation of this case at the April 2nd to 5th 2008 Conference in Dallas, Texas, U.S.A.

REFERENCES